SJEPD030_D.RNA-Seq
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- age_years
- 5.64
- e1_e2
- E2
- umap1_2d
- -7.032145304
- umap2_2d
- -0.982365348
- umap1_3d
- 1.296233011
- umap2_3d
- 2.65592302
- umap3_3d
- 1.353415328
- dataset
- EPN-StJude
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.390
- BILE_ACID_METABOLISM+0.290
- MYOGENESIS+0.270
- APICAL_SURFACE+0.160
- SPERMATOGENESIS+0.160
- PANCREAS_BETA_CELLS+0.080
- COAGULATION+0.050
- XENOBIOTIC_METABOLISM+0.030
- ESTROGEN_RESPONSE_EARLY-0.030
- ESTROGEN_RESPONSE_LATE-0.040
Top 10 suppressed
- MYC_TARGETS_V1-0.630
- UNFOLDED_PROTEIN_RESPONSE-0.600
- E2F_TARGETS-0.580
- MYC_TARGETS_V2-0.560
- PROTEIN_SECRETION-0.560
- MTORC1_SIGNALING-0.540
- G2M_CHECKPOINT-0.520
- ANDROGEN_RESPONSE-0.490
- ANGIOGENESIS-0.470
- PI3K_AKT_MTOR_SIGNALING-0.440
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001530_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.979 |
| 2 | SJEPD007_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.957 |
| 3 | SRR1490465 | GTEX | — | 0.940 |
| 4 | SRR1444460 | GTEX | — | 0.938 |
| 5 | SRR602927 | GTEX | — | 0.937 |
| 6 | SRR1332048 | GTEX | — | 0.934 |
| 7 | SRR1360674 | GTEX | — | 0.934 |
| 8 | SJEPD014_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.932 |
| 9 | SRR1400997 | GTEX | — | 0.932 |
| 10 | SRR1797231 | — | cohortSC | 0.932 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.390 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |